Search Results
Your search for ,dUe matches 5584 pages
Showing 601 - 650Addition of Pazopanib to Concurrent Radiotherapy and Paclitaxel in Anaplastic Thyroid Cancer
In a phase II trial (NRG/RTOG 0912) reported in The Lancet Oncology, Sherman et al found that the addition of pazopanib to concurrent radiotherapy and paclitaxel did not improve overall survival in patients with anaplastic thyroid cancer. Study Details In the U.S. multicenter, double-blind trial,...
ctDNA Analysis May Predict Optimal Treatment for Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented by Bauer et al during the January ASCO Plenary Series session (Abstract 397784). An...
Intensive Remission Induction Chemotherapy vs Less Intensive Approach Prior to Transplant for Relapsed/Refractory AML
Intensive salvage therapy with the goal of achieving complete remission prior to allogeneic hematopoietic cell transplantation (alloHCT) may not be necessary in some patients with relapsed or refractory acute myeloid leukemia (AML), according to the results of the phase III ASAP trial presented at...
The Influence of Structural Racism and Poverty on Outcomes in Leukemia
In the United States, Black American patients with acute myeloid leukemia (AML) have notably worse survival outcomes compared to White patients. In addition, Black patients are less likely to receive intensive chemotherapy and undergo allogeneic stem cell transplants. Many researchers have reported ...
Study Explores the Addition of First-Line Atezolizumab in BRAF V600–Mutant Advanced Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but...
FDA Oncology Center of Excellence Seeks Applications for New Research Funding Opportunities
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Julie A. Schneider, PhD, Associate Director for Research Strategy and Partnerships, OCE; Jennifer J. Gao, MD,...
Addition of Veliparib to Cisplatin in Advanced Triple-Negative Breast Cancer With BRCA-Like and Non–BRCA-Like Phenotype
In a phase II trial (S1416) reported in The Lancet Oncology, Rodler et al found that the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to cisplatin significantly improved progression-free survival in patients with germline BRCA1/2 wild-type advanced triple-negative breast...
Former ASCO President Monica Bertagnolli Welcomed as NCI Director in Capitol Hill Reception
On December 7, 2022, Association for Clinical Oncology (ASCO) Chief Medical Officer and Executive Vice President Julie Gralow MD, FACP, FASCO, attended a reception on Capitol Hill hosted by the One Voice Against Cancer Coalition and the House Cancer Caucus, to welcome former ASCO President Monica...
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
Futibatinib in Previously Treated Patients With Advanced FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
In a phase II study (FOENIX-CCA2) published in The New England Journal of Medicine, Lipika Goyal, MD, and colleagues found that the next-generation, covalently binding FGFR1-4 inhibitor futibatinib showed activity in previously treated patients with unresectable or metastatic FGFR2-altered...
Studies Explore Novel Triplet Combinations in AML
Two separate studies presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition provide preliminary evidence that triplet combinations may have a role in the treatment of acute myeloid leukemia (AML). Both triplets were based on the addition of a third drug to standard ...
ASH 2022: Multiple Myeloma Highlights
The 2022 American Society of Hematology (ASH) Annual Meeting and Exposition was full of interesting abstracts in multiple myeloma. In addition to full coverage of several important presentations, The ASCO Post offers readers quick takes on some studies that could be practice-changing and others...
Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer
The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...
Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-Low Breast Cancer
A pilot study provides a signal that the novel HER2 antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd), is active in the neoadjuvant setting in patients with HER2-low breast cancer. Overall response rates were 75% with T-DXd alone and 63% when T-DXd was combined with endocrine therapy...
Capivasertib Plus Fulvestrant Doubles Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
The combination of capivasertib, an AKT pathway inhibitor, plus fulvestrant, an estrogen receptor antagonist, significantly improved progression-free survival compared with fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results of...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Expert Point of View: Jeremy S. Abramson, MD
Jeremy S. Abramson, MD, Director of Lymphoma, Mass General Cancer Center, Boston, commented on the clinical implications of the TRIANGLE study. “The TRIANGLE trial is a large, three-arm randomized trial addressing two critically important questions in the management of younger patients with mantle ...
Expert Point of View: Jeremy S. Abramson, MD
Jeremy S. Abramson, MD, Director of Lymphoma, Mass General Cancer Center, Boston, commented on the clinical implications of the TRIANGLE study. “The TRIANGLE trial is a large, three-arm randomized trial addressing two critically important questions in the management of younger patients with mantle...
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide in Maintenance Therapy After ASCT in Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Dominik Dytfeld, MD, PhD, and colleagues, an unplanned interim analysis of the phase III ATLAS trial has shown improved progression-free survival with carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide alone as maintenance after autologous stem...
Frequency and Dosage of Radiotherapy in Chemoradiotherapy for Limited-Stage SCLC
As reported in the Journal of Clinical Oncology by Jeffrey Bogart, MD, and colleagues, the phase III CALGB 30610/RTOG 0538 trial has shown no significant difference in overall survival with 70-Gy once-daily vs 45-Gy twice-daily radiotherapy in a chemoradiotherapy regimen for limited-stage small...
Circulating Tumor DNA Profiling and Outcomes in CNS Lymphoma
In a German study reported in the Journal of Clinical Oncology, Mutter et al found that circulating tumor DNA (ctDNA) identified prior to and during treatment was associated with poorer outcomes in patients with central nervous system (CNS) lymphoma. Study Details The study included 92 patients...
Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
Subcutaneous Epcoritamab for Relapsed or Refractory Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Catherine Thieblemont, MD, PhD, and colleagues, findings in a dose-expansion cohort of the phase I/II EPCORE NHL-1 study indicated high activity of the subcutaneous CD3 x CD20 T-cell–engaging bispecific antibody epcoritamab in patients with...
Study Identifies Potential Molecular Differences Between Primary Breast Cancer and Its Metastases
Researchers have identified unique molecular features responsible for the development and progression of metastatic breast cancer, according to a novel study published by Garcia-Recio et al in Nature Cancer. They discovered that one of the key features involves changes in the immune system that are ...
Study Investigates Burden of Cervical Cancer Among Patients Aged 65 and Older
Researchers discovered that a significant number of patients aged 65 years and older may be facing late-stage cervical cancer diagnoses and disease-related mortality—despite U.S. Centers for Disease Control and Prevention (CDC) guidelines recommending that most patients stop screening for cervical...
KEYNOTE-394: Pembrolizumab as Second-Line Therapy in Asian Patients With Advanced HCC
As reported in the Journal of Clinical Oncology by Qin et al, the phase III KEYNOTE-394 trial showed overall and progression-free survival benefits with pembrolizumab vs placebo in previously treated Asian patients with advanced hepatocellular carcinoma (HCC). Study Details The double-blind trial...
Addition of Adjuvant Nab-paclitaxel to Gemcitabine in Pancreatic Ductal Adenocarcinoma
As reported in the Journal of Clinical Oncology by Margaret A. Tempero, MD, and colleagues, the phase III APACT trial has shown no improvement in independently assessed disease-free survival (the study’s primary endpoint) with the addition of adjuvant nab-paclitaxel to gemcitabine in...
Expert Point of View: Seth Wander, MD, PhD
Seth Wander, MD, PhD, Assistant Professor, Mass General Cancer Center, Boston, commented on the findings of the EMERALD trial. “We have seen a large amount of new data emerging related to elacestrant and other novel SERDs [selective estrogen receptor degraders]. Despite initial expectations based...
EMERALD Trial: Elacestrant vs Standard Endocrine Monotherapy for Advanced Breast Cancer After CDK4/6 Inhibition
Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer in the ...
Crizotinib Combined With Chemotherapy in Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
As reported in the Journal of Clinical Oncology by Lowe et al, findings in an arm of the Children’s Oncology Group phase II ANHL12P1 trial (arm CZ) showed high event-free and overall survival rates with the addition of crizotinib to chemotherapy in newly diagnosed pediatric patients with...
Triple Immunotherapy Combination Studied Preclinically for Pancreatic Cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment and significantly improved antitumor responses in...
One in Seven Diagnosed Cancers Is Found by Recommended Screening Tests
Despite widespread awareness of the importance of screening for asymptomatic, early detection of cancer, screening tests exist for only five cancer types. With few recommended cancer screening tests and generally low adherence to cancer screening recommendations, it is difficult to detect cancer...
Study Examines ‘Reconstructive Burnout’ Phenomenon: Patients Who Start Breast Reconstruction After Mastectomy but Don't Complete It
Nearly one-fourth of patients with breast cancer who start breast reconstruction after mastectomy don't complete the reconstructive process. The concept of reconstructive burnout was introduced and discussed in a study published by Halani et al in the January issue of Plastic and Reconstructive...
Silicone Film to Prevent Acute Radiation Dermatitis in Patients With Breast Cancer
In a Canadian phase III trial reported in the Journal of Clinical Oncology, Behroozian et al found that the use of Mepitel film—a silicone-based polyurethane film dressing—significantly reduced the incidence of grade 2 or 3 acute radiation dermatitis vs usual care in at-risk women receiving...
Updated Position Statement on Drug Repository Programs Aims to Increase Access to Treatment
ASCO recently released an updated position statement on drug repository programs. The update shifts ASCO’s position to allow donation of oral cancer drug treatments in an open distribution system—which are drugs that have left the supply chain and have been dispensed to patients. ASCO’s previous...
Mirvetuximab Soravtansine for FRɑ-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On November 14, 2022, the U.S. Food and Drug Administration (FDA) granted mirvetuximab soravtansine-gynx accelerated approval for patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three...
How ASCO and the Oncology Community Came Together to Discuss Progress in Global Cancer Control and the Challenges Ahead
After a 4-year in-person hiatus because of the COVID-19 global pandemic, the World Cancer Congress, hosted by the Union for International Cancer Control (UICC), held its first hybrid in-person and virtual meeting in October in Geneva. The conference brought together more than 2,000 attendees from...
Risk-Reducing Bilateral Mastectomy May Help Women With High-Penetrance Genetic Mutations to Avoid Cancer
“Risk-reducing bilateral mastectomy allows a woman with a high-penetrance breast cancer-causing mutation to avoid an encounter with the experience of breast cancer diagnosis and treatment,” Seema A. Khan, MD, MPH, stated at the 2022 Lynn Sage Breast Cancer Symposium.1 For these women, by avoiding...
How Telemedicine Can Transform Clinical Research and Practice
The COVID-19 pandemic transformed the world, and nowhere more so than in the health-care arena. Significant changes happened almost overnight in the delivery of medical care to focus on the safety and convenience of patients, staff, and providers. Although pilot efforts to integrate telemedicine...
In Stage IV NSCLC, Anti-TIGIT Antibody Boosts Immunotherapy Benefit
In the phase II ARC-7 study, when domvanalimab, a novel antibody that blocks T-cell immunoglobulin and ITIM domain (TIGIT), was added to immunotherapy for patients with stage IV non–small cell lung cancer (NSCLC), the combination resulted in improved response rates and progression-free survival...
Study Finds Medicaid Expansion May Improve Survival Outcomes for Young Adult Patients With Cancer
Researchers have discovered that expanded Medicaid coverage under the Affordable Care Act may lead to better survival outcomes for young adult patients aged 18 to 39 years who have been newly diagnosed with cancer—particularly among those who identify as Hispanic or non-Hispanic Black—according to...
FDA Approves FoundationOne Liquid CDx as a Companion Diagnostic for a Certain Group of Tyrosine Kinase Inhibitors
On December 21, Foundation Medicine, Inc, announced that the U.S. Food and Drug Administration (FDA) approved its FoundationOne Liquid CDx as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R substitutions...
New Approaches Still Needed to Treat Patients With Cancer Who Have Serious Mental Illness
Although mandates by ASCO and the American Cancer Society to meet the needs of underserved populations have drawn much-needed awareness to the issue, patients with cancer who experience bipolar disorder, schizophrenia, and other debilitating mental illnesses continue to experience significantly...
Interim Analysis of Overall Survival in the monarchE Trial
As reported in The Lancet Oncology by Stephen R.D. Johnston, MD, PhD, and colleagues, an interim analysis of overall survival in the phase III monarchE trial has shown no significant benefit with the addition of adjuvant abemaciclib to endocrine therapy in patients with hormone receptor–positive,...
Prostate Cancer Screening With MRI-Targeted vs MRI-Targeted and Systemic Biopsy
In a Swedish study (GÖTEBORG-2) reported in The New England Journal of Medicine, Hugosson et al found that magnetic resonance imaging (MRI)-targeted prostate biopsy was associated with a lower risk of overdiagnosis of clinically insignificant prostate cancer compared with MRI-targeted and...
TIL Therapy vs Ipilimumab in Advanced Melanoma
In a Dutch-Danish phase III trial reported in The New England Journal of Medicine, Rohaan et al found that tumor-infiltrating lymphocyte (TIL) therapy prolonged progression-free survival vs ipilimumab in patients with advanced melanoma. Study Details The open-label trial included 168 patients...
Brain Cancer After CT Scans in Children and Young Adults
In a European cohort study (EPI-CT) reported in The Lancet Oncology, Hauptmann et al found an increased risk of brain cancer with increasing brain radiation dose among children and young adults who had undergone computed tomography (CT) scans. Study Details The study used pooled data from nine...
Impact of Adjuvant Therapy on Outcomes in Patients With Node-Negative Disease After Neoadjuvant Therapy and Resection of Pancreatic Carcinoma
In a retrospective cohort study reported in JAMA Surgery, Hammad et al found that adjuvant therapy was associated with better outcomes vs no adjuvant therapy in patients with node-negative disease after neoadjuvant therapy and resection of pancreatic carcinoma. Study Details The study used data...
Simplified Treatment Regimen Reduces Early Deaths in Patients With APL
The use of a simplified treatment regimen by oncologists—along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts—resulted in a decrease in early deaths from acute promyelocytic leukemia (APL). In the multicenter prospective trial...
